Omar E Hegazi, Samer O Alalalmeh, Moyad Shahwan, Ammar Abdulrahman Jairoun, Mansour M Alourfi, Ghfran Abdulrahman Bokhari, Abdullah Alkhattabi, Saeed Alsharif, Mohannad Abdulrahman Aljehani, Abdulmalik Mohammed Alsabban, Mohammad Almtrafi, Ysear Abdulaziz Zakri, Abdullah AlMahmoud, Khalid Mohammed Alghamdi, Ahmed M Ashour, Nasser M Alorfi
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common disease and has been increasing in recent years. To date, no FDA-approved drug specifically targets NAFLD. METHODS: The terms "Non-alcoholic Fatty Liver Disease" and "NAFLD" were used in a search of ClinicalTrials.gov on August 24, 2023. Two evaluators independently examined the trials using predetermined eligibility criteria. Studies had to be interventional, NAFLD focused, in Phase IV, and completed to be eligible for this review...
2024: Diabetes, Metabolic Syndrome and Obesity